Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

University of Oxford

http://www.ox.ac.uk/

Latest From University of Oxford

Tech Transfer Roundup: Tiba And CEPI Strategize Together On ‘Disease X’

Immix collaborates with Israeli research institutions on BCMA-targeted CAR-T therapy. NeoImmuneTech/NIAID alliance could pave way for “animal rule” approval in acute radiation syndrome.

Tech Transfer Round-Up Deals

Merck KGaA Exec On Gearing For mRNA Prime Time, De-Risking Manufacturing

Benoit Opsomer, vice-president and head of bioprocessing, Asia Pacific, Merck Life Science, explains how recent targeted CDMO buyouts put the German group in pole position with services across the mRNA value chain, even as it supports global players such as BioNTech. Striking multi-country expansion of manufacturing footprint, including in China, is also underway amid rising demand for biopharma single-use assemblies.

Commercial Coronavirus COVID-19

Merck KGaA Exec On Gearing For mRNA Prime Time, De-Risking Manufacturing

Benoit Opsomer, vice-president and head of bioprocessing, Asia Pacific, Merck Life Science, tells Scrip in an interview how recent targeted CDMO buyouts put the German group in pole position with services across the mRNA value chain, even as it supports global players such as BioNTech. Striking multi-country expansion of manufacturing footprint, including in China, is also underway amid rising demand for biopharma single-use assemblies.

Commercial Coronavirus COVID-19

MagGenome On Path To Nanoparticle Adjuvant, Founder Seeks Investment Opportunities

MagGenome, an Indian biotech which develops nanoparticle-based products, is in the early stage of research for a vaccine adjuvant. Scrip spoke to founder Sam Santhosh and CEO and chief scientific officer C N Ramchand to gauge the promise of nanotechnology and the environment in India for cell and gene therapies, among other topics, in this wide-ranging audio interview. 

Research & Development Innovation
See All

Company Information

  • Industry
  • Academic and Research Institutions
  • Other Names / Subsidiaries
    • Oxford University Innovation
UsernamePublicRestriction

Register